Sriram Ryali
Chief Financial OfficerMr. Sriram Ryali, also known as Sri, MBA, is Chief Financial Officer of Caribou Biosciences, Inc. from January 2, 2025. Mr. Ryali served as Chief Financial Officer at Codexis, Inc. since January 24, 2023. He had been Chief Financial Officer of Eiger BioPharmaceuticals, Inc. since December 2018 until January 20, 2023. Mr. Ryali has many years of finance and commercial experience. Prior to joining Eiger, Mr. Ryali was Vice President, Finance from 2017 to 2018 and Senior Director, Finance from 2015 to 2017 at Aimmune Therapeutics, Inc. Before joining Aimmune, Mr. Ryali was Senior Director, Financial Planning & Analysis at Jazz Therapeutics, plc in 2015 and held a series of different finance-related positions of increasing responsibility at Onyx Pharmaceuticals, Inc. and Amgen, Inc. from 2004 to 2015. Previously, Mr. Ryali led U.S. Financial Planning and Analysis at Jazz Pharmaceuticals and was Head of Corporate Finance at Onyx Pharmaceuticals, Inc., until the company was acquired by Amgen, Inc. in 2013. Following the acquisition, Mr. Ryali continued as Head of R&D, Technical Operations and Medical Affairs Finance at Onyx. Mr. Ryali began his career in biopharmaceutical companies at Amgen Inc., where he held positions of increasing responsibility in the finance organization. Mr. Ryali earned a BA from University of California, Los Angeles (UCLA) with a double major in Economics and Microbiology, Immunology & Molecular Genetics and an MBA from UCLA Anderson School of Management.
Positions
- Company NameCaribou Biosciences, Inc.Stock CodeCRBUPositionChief Financial OfficerColleagues
- RERachel E. HaurwitzCo-Founder, CEO, President & Director
- ALAndrew L. GuggenhimeIndependent Chairman
- BGBarbara G. McClungChief Legal Officer & Corporate Secretary
- JAJennifer A. DoudnaCo-founder & Member of Scientific Advisory Board
- RFRyan FischesserInterim Principal Accounting Officer & Controller
- NSNatalie SacksIndependent Director
- SNScott N. BraunsteinIndependent Director
